|
MVA and DNA Based SARS-CoV-2 Vaccines
Application
Modified Vaccinia virus Ankara (MVA)- and deoxyribonucleic acid (DNA)-based vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Key Benefits
Safety profile is known.
Demonstrated antiviral activity against related Coronaviruses.
Single dose of vaccination was shown to be effective against related Coronaviruses...
Published: 2/13/2025
Contributor(s): Rama Rao Amara, Sailaja Gangadhara
|
|
Vaccine-pulsed Dendritic Cells as a Treatment for Aggressive Breast Cancers
Application
Immunotherapy for HER2+ and triple-negative breast cancer.
Key Benefits
Autologous vaccine comprising patient-specific tumor antigens and immune stimulatory components against aggressive breast cancers.
Prepared outside of the body and then administered to patients.
Preclinical data indicate treatment decreases tumor growth and improves...
Published: 2/13/2025
Contributor(s): Periasamy (Selva) Selvaraj, Luis Munoz, Ramireddy Bommireddy, Christopher Pack, Shaker Reddy, Sampath Ramachandiran
|
|
Novel Endoglycosidase Derivatives Treating Diseases of the Adaptive Immune System
Application
Protein-based therapeutics for the treatment of IgG-mediated diseases.
Key Benefits
A new class of endoglycosidases for the treatment of IgG-mediated diseases.
Four novel compounds have been developed that exhibited robust in vitro activity.
Potential to become first-in-class medications for dysregulation of the adaptive immune system,...
Published: 2/13/2025
Contributor(s): Eric Sundberg, Diego Sastre, Jonathan Du, Jeffrey Ravetch, Stylianos Bournazos
|
|
Vital Sign Trajectory Algorithm
Application
A precision medicine algorithm that reduces mortality in sepsis patients by individualizing and targeting specific therapies to specific patients.
Key Benefits
An algorithm that uses bedside routine vital signs to optimize the precision treatment of sepsis.
Clinical data show the ability of the algorithm to identify a subset of patients...
Published: 2/13/2025
Contributor(s): Sivasubramanium (Siva) Bhavani
|
|
Improving Pediatric Asthma Management for Urban Families
Application
Home-based family psychoeducational intervention for low-income children with persistent asthma.
Key Benefits
Medical and psychosocial needs of patients and family members can be addressed simultaneously.
Significantly improved asthma management and caregiver stress in randomized controlled clinical trial.
Market Summary
Asthma...
Published: 2/13/2025
Contributor(s): Marianne Celano, Lisa Kobrynski, Chanda Holsey
|
|
Methods for Enhancing MSC Therapeutic Potential for Treatment of Osteoarthritis by Measuring and Targeting Intracellular Pathways
Application
Highly transformative new strategy to enhance mesenchymal stromal cell consistency and efficacy for taking MSC therapies to clinical stage.
Key Benefits
Currently there is no method to determine if an MSC donor line will be therapeutically effective.
Provides a point of use assay in the clinical setting which can determine MSC efficacy...
Published: 2/13/2025
Contributor(s): Nick Willett, Levi Wood, Jay McKinney
|
|
KRAS Mutant Protein-Protein Interaction Targets and Inhibitors for Cancer Therapy
Application
Immunotherapeutic agent and biosensor for KRASG12V mutation in tumor cells.
Key Benefits
First in class, targeted immunotherapy for patients presented with KRASG12V mutation.
Attenuates immune suppression associated with KRASG12V-positive cancers.
Market Summary
The KRASG12V mutation, representing 85% of all cancer mutations, is...
Published: 2/13/2025
Contributor(s): Haian Fu, Cong Tang, Xiulei Mo
|
|
Interleukin-37 to Enhance Effectiveness of CAR T-cell Therapy
Application
IL-37-expressing CAR T-cells to treat B-cell acute lymphoblastic leukemia.
Key Benefits
Boosts the function of aged T-cells.
Enhances the effectiveness of CAR T-cell therapy.
Therapeutic potential to overcome aging-associated immune-senescence.
Potent suppressor of chronic inflammation or pro-inflammatory cytokines.
Market...
Published: 2/13/2025
Contributor(s): Curtis Henry, Sunil Raikar, Sarwish Rafiq
|
|
HIV-1 Clade C Protein Immunogen as HIV-1 Vaccine
Application
Novel stabilized HIV-1 Clade C gp140 trimeric immunogen useful as a vaccine.
Key Benefits
Vaccine for HIV-1 infections.
Induces both neutralizing and V1V2 scaffold directed antibody responses.
V1V2 scaffold directed antibodies bind to multiple strains of HIV-1 from different clades including Clades B and C.
Market Summary
HIV-1...
Published: 2/13/2025
Contributor(s): Rama Rao Amara, Sailaja Gangadhara, Tiffany Styles, Anusmita Sahoo
|
|
Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular STING Pathway
Application
Vaccine formulation of an activator of the stimulator of interferon genes (STING) pathway and saponin adjuvant for enhanced protection of aged population.
Key Benefits
Significantly improved protective immunity of vaccine in the aged.
More efficient than the current methods of influenza vaccination of population 65 years of age or...
Published: 2/13/2025
Contributor(s): Elena Vassilieva, Richard Compans
|
